Impact of a Prior Authorization for Pregabalin on Health Plan Drug ExpendituresByGary Bazalo, MS, MBA,Richard C. Weiss, MS,Ashish V. Joshi, PhDJune 1st 2010
Pregabalin: An Alpha2-delta (a2-d) Ligand for the Management of FibromyalgiaByLesley Arnold, MD,Philip Mease, MD,Stuart Silverman, MDMay 28th 2010
Financial and Clinical Characteristics of Fibromyalgia: A Case-Control ComparisonByAna Palacio, MD, MPH,Claudia L. Uribe, MD, MHA,Hua Li, MD, PhD,John Hanna, MBA,Michael Deminski, MS, RPh,Jose Alvir, DrPH,Arthi Chandran, MPH,Robert Sanchez, RPh, MSMay 28th 2010
Initial Use of Pregabalin, Patterns of Pain-Related Pharmacotherapy, and Healthcare Resource Use Among Older Patients With FibromyalgiaByMugdha Gore, PhD, BPharm,Alesia Sadosky, PhD, MPH, MBA,Gergana Zlateva, PhD,Daniel Clauw, MDMay 28th 2010
Patterns of Healthcare Utilization and Cost in Patients With Newly Diagnosed FibromyalgiaByAriel Berger, MPH,Alesia Sadosky, PhD, MPH, MBA,Ellen M. Dukes, PhD,John Edelsberg, MD, MPH,Gergana Zlateva, PhD,Gerry Oster, PhDMay 28th 2010
